CaroGen

CaroGen is an immunotherapy company that develops vaccine candidates that target hepatitis B and C, as well as other viral agents. The company was founded by Bijan Almassian and Valerian Nakaar, in Hamden, Connecticut, United States.

The company is interested in developing and creating recombinant and replication proficient-virus like vesicle-based vaccines. CaroGen looks to connect customers with generic and brand medicine suppliers in the world. The company provides products that assist with allergies, anti-fungal, anti-viral, anti-depressants, anti-bacterials, antibiotics, arthritis, asthma, birth control, blood pressure, cancer, cardiovascular problems, diabetes, hepatitis C virus, and HIV as well.

COVID-19

In response to the outbreak of coronavirus (COVID-19), CaroGen and scientists form Yale have launched efforts to work on a vaccine to fight against the virus. The team claims that a foundation for a novel COVID-19 vaccine was established in their laboratory around a decade ago, and hopes to have human clinical studies within months.

A fully developed vaccine can take up to three years to earn approval to be used in patients, however the company believes there will be need for a vaccine in coming years. The company has assisted during other outbreaks including the Zika virus.